What is your approach to chemoprevention for HR+ DCIS in the ipsilateral breast in a patient who already completed 7 years of an AI for a prior HR+ invasive breast cancer?

This is a not-uncommon scenario. What is the appropriate use of endocrine therapy after ipsilateral breast tumor recurrence or second primary breast cancer in a patient who has recently completed hormonal therapy?

As shown in the Breast Cancer Prevention Trial (P-1), MAP.3, and IBIS II, both SERMs an...

In this case, chemo prevention is obviously for the contralateral breast. I agree with Dr. @Dr. First Last in considering an AI or tamoxifen if prior ET was more than 5 years ago. What is the use of switching to another AI or tamoxifen for chemo prevention while they are already on ET for invasive d...